Developing a New Cognitive-Impairment Measure for Korean Cancer Patients

Hee-Ju Kim, Ph D, RN a, Andrea M. Barsevick, Ph D, RN, AOCN®, FAAN b The Catholic University of Koreaa, Thomas Jefferson Universityb

What we learned

- The impact of cancer and its treatment on cognitive impairment has become a focus for oncology research and practice.
- To identify and manage cognitive impairment, practical brief instruments are needed.
- The Brief Perceived Cognitive-Impairment Scale, developed in Korean, is a valid and reliable instrument.

Background

• Practical brief measures are needed for clinicians and researchers to identify and to effectively manage cognitive impairment in cancer patients.

Purpose

• The purpose of the study was to develop and to evaluate the reliability (i.e.,internal consistency reliability) and validity (i.e.,factorial, convergent, concurrent, and known-group validity) of the Brief Perceived Cognitive Impairment Scale-Korean (BPCIS-K).

Method

- The BPCIS-K was constructed with 6 items evaluating key aspects of cognitive impairments occurring in cancer patients.
- A total of 249 cancer patients from a university hospital and a total of 120 healthy adults participated for evaluation.
- Cronbach's alpha, item-total correlations; Confirmatory factor analysis; Pearson's correlations with the Functional Assessment of Cancer Therapy—Cognitive Function(FACT-Cog), and the Functional Assessment of Chronic Illness Therapy—Fatigue(FACIT-F); *t* tests were tested.

Results

- The BPCIS-K has high internal consistency reliability. Cronbach's alpha was .92 and Item-total correlations ranged from .76 to .81.
- The scale is uni-dimensional in confirmatory factor analysis.
- The scale has a good convergent and concurrent validity as evidence by the high association with cognitive impairment measure (r = -.91) and moderate correlation with a fatigue measure (r=-.52,p<.001).
- In known-groups validity, cancer patients, female cancer patients, and patients undergoing treatment experienced more severe impairment than healthy subject, male patient, and patient waiting treatment (p<.001,p=.05,p=.08,respectively).

Table 1.Score Distribution and Internal Consistency Reliability in Cancer Patients (N = 249)

							alpha
Item	Score			Skew			if item is
description	range	Mean	SD	ness	osis	total corr	deleted
Item 1: poor concentration	0-4	0.81	0.94	1.23	1.32	0.76	0.91
Item 2: impaired memory	0-4	1.07	1.05	.87	0.17	0.77	0.91
Item 3: difficulty in decision making	0-4	0.83	0.99	1.08	0.52	0.78	0.91
Item 4: difficulty in forming multiple complex thought	0-4	1.09	1.12	.83	-0.08	0.76	0.91
Item5:mental slowness in responding to others	0–4	0.78	0.97	1.26	1.10	0.81	0.91
Item6: difficulty in adequate word finding and response		0.83	1.04	1.18	0.71	0.81	0.91
Total scale score	0–24	5.41	5.21	1.06	0.79		

Table 2. Known Group Validity

	Cancer patients n=249	controls		Male	patients Female n=148	
0.0040	1.7.41	3.62 (3.54)	3.85***	4.63 (4.58)	5.95 (5.55)	-1.97 $(p = .05)$

Note.^a Missing data. Total score ranged from 0to24, anchor was: 0=never, 1=one a week, 2=2 or 3 times a week, 3= almost everyday; 4=several times a day, p<.05, p<.01, p<.01

Results

Table 3. Convergent and Concurrent Validity the Brief Perceived Cognitive Impairment Scale in Cancer Patients (N = 249)

	Pearson r with The FACT- cognitive impairment subscale	Pearson r with FACIT- Fatigue
Total Scale Score	91***	52***
Item 1: poor concentration	76***	50***
Item 2: impaired memory	78***	39***
Item 3: difficulty in decision making	75***	41***
Item 4: difficulty in forming multiple complex thought	72***	44***
Item5:mental slowness in responding to others	81***	47***
Item6:difficulty in adequate word finding and response	83***	45***

Note.. Due to the list wise deletion, sample size varied, having smallest sample size 244 in correlation with the FACT-cognitive impairment subscale,***p < .001.

Conclusion

The Brief Perceived Cognitive
Impairment Scale-Korean is a valid and reliable measure to assess cognitive impairment for cancer patients, particularly in concentration, memory and executive function

Reference

Ono et al., (2015). A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. *Frontiers in Oncology, 5,* 59.

Park et al.(2015). The psychometric properties of the Korean version of the Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) in Korean patients with breast cancer. *Supportive Care in Cancer*, 23, 2695–2703.

Polit, et al., (2007). Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. *Research in Nursing & Health*, *30*, 459–467.

